Spiroxatrine derivatives towards 5-HT1A receptor selectivity

[1] Caldwell JP(2007)Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands Bioorg Med Chem Lett 17 2281-2284

[2] Matasi JJ(2001)Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors Eur J Pharmacol 428 29-36

[3] Zhang H(2000)Synthesis of (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties Eur J Med Chem 35 839-851

[4] Fawzi A(2000)High-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor J Med Chem 43 1329-1338

[5] Tulshian DB(2005)Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): ligand-based analysis of structural factors influencing intrinsic activity at NOP AAPS J 7 E345-E352

[6] Zaveri N(2014)Synthesis, enantiomeric separation and docking studies of spiropiperidine analogues as ligands of the nociceptin/orphanin FQ receptor MEDCHEMCOMM 5 973-983

[7] Polgar WE(2014)1,4-Dioxolane-triazaspirodecanone derivatives as nociceptin/orphanin FQ receptor ligands Med Chem Res 23 4642-4656

[8] Olsen CM(2015)Synthesis and structure-activity relationships of triazaspirodecanone derivatives as nociceptin/orphanin FQ receptor ligands Chem Biol Drug Des 86 447-458

[9] Kelson AB(2011)Biased agonism at serotonin 5-HT1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders Neuropsychiatry (London) 1 149-164

[10] Grundt P(2019)Multitarget 1,4-dioxane compounds combining favorable D 2 -like and 5-HT 1A receptor interactions with potential for the treatment of Parkinson’s Disease or Schizophrenia ACS Chem Neurosci 10 2222-2228

[1] Caldwell JP(2007)Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands Bioorg Med Chem Lett 17 2281-2284

[2] Matasi JJ(2001)Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors Eur J Pharmacol 428 29-36

[3] Zhang H(2000)Synthesis of (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties Eur J Med Chem 35 839-851

[4] Fawzi A(2000)High-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor J Med Chem 43 1329-1338

[5] Tulshian DB(2005)Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): ligand-based analysis of structural factors influencing intrinsic activity at NOP AAPS J 7 E345-E352

[6] Zaveri N(2014)Synthesis, enantiomeric separation and docking studies of spiropiperidine analogues as ligands of the nociceptin/orphanin FQ receptor MEDCHEMCOMM 5 973-983

[7] Polgar WE(2014)1,4-Dioxolane-triazaspirodecanone derivatives as nociceptin/orphanin FQ receptor ligands Med Chem Res 23 4642-4656

[8] Olsen CM(2015)Synthesis and structure-activity relationships of triazaspirodecanone derivatives as nociceptin/orphanin FQ receptor ligands Chem Biol Drug Des 86 447-458

[9] Kelson AB(2011)Biased agonism at serotonin 5-HT1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders Neuropsychiatry (London) 1 149-164

[10] Grundt P(2019)Multitarget 1,4-dioxane compounds combining favorable D 2 -like and 5-HT 1A receptor interactions with potential for the treatment of Parkinson’s Disease or Schizophrenia ACS Chem Neurosci 10 2222-2228